Smaller multiplex molecular panels of five or fewer targets will be covered, while a determination of gastrointestinal panel coverage is expected soon.
In the longer term, the two firms plan to use PlexBio's multiplexing technology to develop a full menu of infectious disease assays.
The Gastrointestinal Pathogen Panel is the first of a number of planned infectious disease syndromic panels on the firm's PCR-based system.
The acquisition merges OvaGene's liquid biopsy technology and molecular diagnostics with Etta's point-of-care system.
The assay was demonstrated to be as effective as microscopy and a rapid immunoassay at detecting Plasmodium falciparum in a sample of febrile patients in Nigeria.
Building on a recent point-counterpoint in the Journal of Clinical Microbiology, lab directors discuss pros and cons of large MDx panels for infectious disease testing.
Originally published May 7.
Strong sales of its clinical systems and consumables pushed the firm's top line up 35 percent, while Cepheid turned in its third consecutive quarter of GAAP profitability.
The acquisition is expected to help build Myriad's companion diagnostics franchise.
Microsoft co-founder Paul Allen also contributed to brain research, NPR reports.
The New York Times reports on the shifting interpretations of what some genetic variants mean over time.
In Cell this week: investigation of metastatic tumor evolution, more than 16,000 genetic variants introduced into the budding yeast model organism, and more.
MIT's Technology Review reports on Genentech's pursuit of personalized cancer vaccines.